On June 11, 2025, the Delaware Court of Chancery found Alexion Pharmaceuticals liable for more than $180 million in damages to former stockholders of Syntimmune, Inc., following the Court’s September 2024 ruling that Alexion...more
6/19/2025
/ Biotechnology ,
Breach of Contract ,
Clinical Trials ,
Commercially Reasonable Efforts ,
Contract Disputes ,
Contract Terms ,
Damages ,
Life Sciences ,
Merger Agreements ,
Mergers ,
Pharmaceutical Industry
In 2014, the Delaware Supreme Court held in Kahn v. M&F Worldwide Corp. (“MFW”) that a court will apply the entire fairness standard of review to freeze-out merger transactions between a controlled corporation and its...more
In two recent rulings, the New York Supreme Court rejected settlements arising from lawsuits in which plaintiff stockholders challenged the defendant public companies’ merger-related disclosures. The court in each case...more